Adherex is developing eniluracil to improve the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most commonly used anticancer drugs. The clinical study will primarily
The patented therapeutic use of CD83 was initially filed by Dana-Farber Cancer Institute. Beckman Coulter then gained license to it and under the latest agreement, retains rights to
US orphan drug designation aims to encourage the development of drugs involved in the diagnosis, prevention or treatment of a medical condition affecting fewer than 200,000 people in
The extension calls for additional funding of C$662,500 from Defence R&D Canada (DRDC) to execute a preclinical efficacy study of inhaled liposomal ciprofloxacin for post-exposure prophylaxis against inhalational
The multi-center trial was designed to evaluate the combination therapy in advanced pancreatic cancer patients who have not undergone chemotherapy. The study enrolled 39 patients with primary advanced
This second clinical protocol for Chemophase is designed to evaluate multiple intravesical (into the bladder) administrations of Chemophase along with the widely used anticancer drug mitomycin in patients
INS50589 is a selective and reversible inhibitor of the platelet P2Y12 adenosine diphosphate receptor. The phase II clinical trial is a randomized, double-blind comparison of three doses of
This is the first preventive HIV vaccine trial to be conducted in Zambia, and will take place at the Zambia Emory HIV Research Project Center in Lusaka. It
Array’s MEK inhibitor, ARRY-438162, will be evaluated in dose escalation studies in normal, healthy volunteers. Array scientists have previously demonstrated ARRY-438162 to be potent, selective, well-tolerated and efficacious
According to the terms of the agreement, ImQuest will immediately complete final preclinical and clinical drug development programs for the agents. Samjin will retain the rights to manufacture
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.